Angiotensin Converting Enzyme (ACE) Inhibition and Peripheral Arterial Disease

• Status: Completed
• Trial end date: 2012-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Leg pain caused by peripheral arterial disease (PAD) can severely impede walking ability. Our preliminary findings indicate that the drug ramipril is much more effective in improving walking ability than current therapies. To be accepted as a new treatment for PAD these findings require validation in a much larger clinical trial.We propose to examine the effects of ramipril therapy for 6 months in a randomized, controlled trial of patients with PAD. If positive, this study will identify ramipril as a potential new therapy for PAD.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayside Health
• Treatments: Angiotensin-Converting Enzyme Inhibitors; Ramipril

Criteria

Inclusion Criteria:

• Ankle brachial index of <0.9 in at least one leg

• History of intermittent claudication (unilateral or bilateral)

• A stable medication regimen for at least 6 months

Exclusion Criteria:

• Limiting coronary artery disease

• Renal failure (serum creatinine > 0.20 mmol/L)

• Current treatment or treatment within the previous 6 months with ACE inhibitors or angiotensin II receptor antagonists